IPSS-M Identifies Hidden High-Risk Biology in Clinically Lower-Risk MDS, Guiding Earlier Transplant Decisions
核心洞察
The Molecular International Prognostic Scoring System (IPSS-M (搜索)) formalizes incorporation of molecular mutations into risk assessment for myelodysplastic syndromes (搜索), identifying patients with hidden high-risk biology.
Approximately 30% of patients with clinically lower-risk MDS can be re-stratified to higher-risk categories using IPSS-M (搜索), prompting earlier transplant evaluation.
Patients classified as moderate-high, high-, or very high-risk by IPSS-M (搜索) may be considered for allogeneic transplant from the outset without intermediary therapy.
The Molecular International Prognostic Scoring System (IPSS-M (搜索)) is reshaping how clinicians identify patients with myelodysplastic syndromes (搜索) (MDS) who harbor hidden high-risk biology despite appearing to have clinically lower-risk disease. By incorporating molecular mutations into prognostic assessment, the tool formalizes a practice that experienced hematologists had long employed anecdotally—flagging patients for earlier allogeneic transplant evaluation before they cycle through all standard lower-risk treatments.
Amer Zeidan, MBBS, MD, professor of medicine at Yale School of Medicine and chief of the Division of Hematologic Malignancies at Yale Comprehensive Cancer Center (搜索), explained that even before IPSS-M (搜索), clinicians recognized that certain patients classified as lower-risk by the IPSS or IPSS-R had worse outcomes due to adverse molecular mutations. "We would consider those patients for transplant relatively earlier in their disease course. We would not wait until they had gone through all the traditional treatments because we know their survival is somewhat limited, especially for younger patients or others who are candidates for allogeneic transplant," Zeidan said during a Frontline Forum discussion.
Formalizing Molecular Risk Assessment
The IPSS-M (搜索), described in a landmark 2022 publication by Bernard and colleagues in NEJM Evidence, integrates molecular mutation data into the prognostic framework. Zeidan noted that the score now allows clinicians to systematically identify patients who are moderate-high, high-, or very high-risk and consider them for transplant from the outset. "There are patients who do not need intermediary therapy before transplant, such as those with low blasts and good counts but adverse risk by the IPSS-M," he said, emphasizing that treatment in this setting remains highly individualized.
Raji Shameem, MD, a hematologist and medical oncologist at the Orlando Health Cancer Institute, echoed this perspective, stating that she has incorporated IPSS-M (搜索) into her practice for patient stratification. "I don't perform transplant, but it helps me identify those who need a transplant evaluation," Shameem said. She estimated that approximately 30% of patients can be re-stratified to higher-risk categories, while some may be moved to lower risk, aiding in the selection of appropriate disease-modifying therapies.
Eliminating the Intermediate-Risk Ambiguity
Akriti Jain, MD, a hematologist and medical oncologist at Cleveland Clinic, highlighted another key advantage of the IPSS-M (搜索): the elimination of the intermediate-risk category that existed in the IPSS-R. "IPSS-M has been great because it helped divide patients into lower risk and higher risk, removing the intermediate risk in IPSS-R, which was always that tough patient to treat, because intermediate risk can sometimes fall in lower risk and other times in higher risk," Jain said. This binary stratification streamlines the diagnostic process and clarifies treatment selection, reducing clinical uncertainty for a patient population that previously occupied a therapeutic gray zone.
The integration of molecular data into prognostic scoring represents a significant advancement in MDS management, enabling more precise risk-adapted treatment strategies. For community and academic clinicians alike, the IPSS-M (搜索) provides an evidence-based framework to identify patients whose molecular profile warrants earlier consideration of curative-intent transplant, potentially altering the disease trajectory for those with otherwise occult high-risk biology.